No abstract

A substantial fraction of eukaryotic transcripts are considered long non-coding RNAs (lncRNAs), which regulate various hallmarks of cancer. Here, we discovered that the lncRNA HOXB-AS3 encodes a conserved 53-aa peptide. The HOXB-AS3 peptide, not lncRNA, suppresses colon cancer (CRC) growth. Mechanistically, the HOXB-AS3 peptide competitively binds to the ariginine residues in RGG motif of hnRNP A1 and antagonizes the hnRNP A1-mediated regulation of pyruvate kinase M (PKM) splicing by blocking the binding of the ariginine residues in RGG motif of hnRNP A1 to the sequences flanking PKM exon 9, ensuring the formation of lower PKM2 and suppressing glucose metabolism reprogramming. CRC patients with low levels of HOXB-AS3 peptide have poorer prognoses. Our study indicates that the loss of HOXB-AS3 peptide is a critical oncogenic event in CRC metabolic reprogramming. Our findings uncover a complex regulatory mechanism of cancer metabolism reprogramming orchestrated by a peptide encoded by an lncRNA.

Hepatocellular carcinoma (HCC) is a major cause of cancer-related death worldwide and currently has the fastest rising incidence of all cancers. Sorafenib was originally identified as an inhibitor of multiple oncogenic kinases and remains the only approved systemic therapy for advanced HCC. However, acquired resistance to sorafenib has been found in HCC patients, which results in poor prognosis. Here, we showed that metallothionein (MT)-1G is a critical regulator and promising therapeutic target of sorafenib resistance in human HCC cells. The mRNA and protein expression of MT-1G is remarkably induced by sorafenib, but not other clinically-relevant kinase inhibitors (e.g., erlotinib, gefitinib, tivantinib, vemurafenib, selumetinib, imatinib, masitinib, and ponatinib). Activation of transcription factor nuclear factor erythroid 2-related factor 2 (NRF2), but not p53 and hypoxia-inducible factor 1-alpha (HIF1α), is essential for induction of MT-1G expression following sorafenib treatment. Importantly, genetic and pharmacological inhibition of MT-1G enhances the anticancer activity of sorafenib in vitro and in tumor xenograft models. The molecular mechanisms underlying the action of MT-1G in sorafenib resistance involves the inhibition of ferroptosis, a novel form of regulated cell death. Knockdown of MT-1G by RNAi increases glutathione depletion and lipid peroxidation, which contributes to sorafenib-induced ferroptosis. Conclusion These findings demonstrate a novel molecular mechanism of sorafenib resistance and also suggest that MT-1G is a new regulator of ferroptosis in HCC cells.

No abstract

Density functional theory calculations have been performed to investigate the effect of Sn on the catalytic activity and selectivity of Pt catalyst in propane dehydrogenation. Five models with different Sn to Pt surface molar ratios are constructed to represent the PtSn surfaces. With the increase of the Sn content, the d-band of Pt is broadened, which gives rise to a downshift in the d-band center on the PtSn surfaces. Consequently, the bonding strength of propyl and propylene on the alloyed surfaces is lowered. With the decomposition of the adsorption energy, the change in the surface deformation energy is predicted to be the dominant factor that determines the variation in the adsorption energy on the surface alloys, while on the bulk alloys the change in the binding energy makes a major contribution. The introduction of Sn lowers the energy barrier for propylene desorption and simultaneously increases the activation energy for propylene dehydrogenation, which has a positive effect on the selectivity toward propylene production. Considering the compromise between the catalytic activity and selectivity, the Pt 3 Sn bulk alloy is the best candidate for propane dehydrogenation.